DENVER, Colo. (247marketnews.com) — Today’s market spotlight spans companies navigating critical catalysts; NeOnc Technologies Holdings (NASDAQ:NTHI) is drawing attention with brain-cancer research milestones and a closely watched technical rebound setup; BIO-key International (NASDAQ:BKYI) is expanding its government cybersecurity footprint in the Gulf; STAK (NASDAQ:STAK) is working to build on a return to profitability; Biohaven (NYSE:BHVN) faces pivotal clinical and regulatory questions across its drug pipeline; Exascale Labs Holdings (NASDAQ:XLAB) is pursuing AI infrastructure growth following a multimillion-dollar GPU server agreement; and WISeSat.Space (NASDAQ:SAIQ) is advancing satellite-based cybersecurity and post-quantum communications.
NeOnc’s Brain-Cancer Story Meets a Technical Rebound Setup
NeOnc (NASDAQ:NTHI) is entering a high-visibility stretch as its investigational brain-cancer programs, Abu Dhabi expansion and technical chart setup converge. The company is scheduled to appear on Health Uncensored with Dr. Drew on Fox Business Network on Sunday, October 25, at 5:30 p.m. ET. CEO Amir F. Heshmatpour and Chief Scientific Officer Thomas Chen, MD, PhD, are expected to introduce the company to a broader audience by discussing NEO100 and the challenge of delivering potential therapies to brain tumors across the blood-brain barrier.
The international development story is advancing, too, as NeOnc announced an MOU with Abu Dhabi’s Department of Health covering proposed scientific exchange, specialist training, real-world evidence and evaluation of potential clinical research opportunities. Two children in Abu Dhabi are receiving investigational NEO100 through the company’s Compassionate Care program, with a third expected to join, according to the announcement. Separately, the company reported early improvement in a critically ill three-year-old boy, whose treating physicians said he was breathing independently and beginning to move his legs after treatment began.
The technical picture adds another layer to the story. In the October 21 chart snapshot supplied for this editorial, NTHI was at a reference price of $2.89, above its 9-day exponential moving average near $2.79 and VWAP near $2.87. The daily MACD histogram had turned slightly positive, while resistance around $2.96 and $3.00 defined the immediate test. A sustained move above $3.00 with stronger volume would improve the technical picture; the $3.30–$3.40 zone, including the declining 50-day EMA near $3.38, is the next area to watch. Support sits around $2.75–$2.80, with approximately $2.50 marking the recent low.
Reported short interest rose from 522,311 shares on September 15 to 757,739 on September 30, an increase of approximately 45.1%. The October 21 snapshot showed roughly 98,900 shares traded versus a displayed 60-day average near 208,500. Those figures suggest a setup worth monitoring, but lower volume does not by itself prove selling pressure is exhausted, and short interest alone cannot predict a squeeze. The supplied technical analysis also cites analyst price targets of $13, $15, $20 and $20, averaging $17. The next major scheduled catalyst is the November 17 FDA meeting concerning NEO212’s proposed Phase 2 study design and potential regulatory pathways.
BIO-key International- 7 Gulf Customers in 6 Months Put Identity Security in Focus
BIO-key International (NASDAQ:BKYI) is building its regional growth narrative around passwordless authentication, biometric identity and government cybersecurity. Its latest Middle East government customer announcement adds another potential foothold in a market where agencies are modernizing access controls and strengthening defenses against compromised credentials. The company says it has added seven new customers in the Gulf region over six months.
The product strategy combines its PortalGuard identity and access management platform with Passkey:YOU FIDO2 passwordless authentication, the WEB-key biometric engine and EcoID III fingerprint scanners. The company’s Identity-Bound Biometrics approach seeks to connect authentication directly to the individual rather than relying exclusively on passwords, devices or tokens. BIO-key is delivering the new deployment with regional integration partner VaporVM. A senior technical official at the unnamed institution said, “The transition to biometric authentication has been seamless for our users.” The company has also partnered with Al Majlis Group to expand identity security across the Arabian Gulf and received FIDO Alliance full certification for Passkey:YOU in September.
Revenue Growth Returns STAK to Profitability, but Margins Need Watching
STAK’s (NASDAQ:STAK) latest annual results offer a clearer financial story, as the oilfield equipment and specialized vehicle manufacturer reported fiscal 2026 revenue of $28.2 million, up 13.21% from $24.9 million in fiscal 2025. More notably, the company returned to profitability, recording approximately $0.4 million in net income after a $5.7 million loss in the prior fiscal year. The results highlight how product-mix changes and expense controls have reshaped its financial performance.
Specialized oilfield vehicles were the principal growth engine. Revenue from that category increased 103.35% to $22.2 million, while specialized oilfield equipment revenue fell 53.89% to $5.5 million. STAK said it shifted resources toward higher-priced vehicles and equipment development. The average selling price of its specialized oilfield vehicles rose 41.85%, from $29,564 to $41,936.
The turnaround comes with caveats. Gross profit declined 3.07% to $7.5 million, and gross margin narrowed from 30.86% to 26.43%, reflecting higher production costs and the evolving product mix. Operating expenses fell 41.06% to $6.4 million, helped by lower general and administrative expenses and the absence of share-based compensation expense.
Biohaven’s Broad Drug Pipeline Faces Critical Test as Licensing Deals Expand Opportunity
Biohaven (NYSE:BHVN) is advancing a diverse clinical pipeline spanning neurological disorders, immunology and oncology, while licensing agreements offer a potential route to broader commercialization. One of its most significant recent business developments came October 8, when the company announced a strategic licensing agreement with Ono Pharmaceutical covering extracellular IgG degraders in Japan and selected Asian markets. The lead candidate, BHV-1300, is in Phase 3 development for Graves’ disease. The agreement adds a regional partner to a program targeting a significant unmet medical need and illustrates Biohaven’s effort to turn its research platform into a broader commercial opportunity.
The company’s pipeline extends beyond antibody degradation. Biohaven reported that clinical data for BHV-1530, an investigational FGFR3-directed antibody-drug conjugate with a proprietary TopoIx payload, had been selected for an oral presentation at the EORTC-NCI-AACR Symposium in 2026. It also began enrolling patients in a combination study evaluating BHV-1530 with Regeneron’s cemiplimab. Separately, the company has been developing opakalim for epilepsy and taldefgrobep alfa for obesity, among other programs.
Exascale Labs- AI Infrastructure Moves from Revenue Growth to Bigger Hardware Contract
Exascale Labs (NASDAQ:XLAB) is positioning itself in the infrastructure layer of the artificial intelligence economy, supplying GPU-as-a-Service capabilities and high-performance computing equipment. Its fiscal 2026 results, reported in September, showed revenue increasing 111% to $14.8 million from $7.0 million in fiscal 2025. The company also completed its business combination and began Nasdaq trading under XLAB in August. That rapid revenue growth gives the company a more concrete commercial base as it pursues demand for AI compute capacity.
A major follow-on development arrived in October. In an agreement dated October 8 and disclosed in a subsequent SEC filing, Exascale agreed to supply Sunon Inc., a U.S. subsidiary of Taiwan-listed Sunonwealth Electric Machine Industry, with 12 NVIDIA HGX B300 GPU servers containing 96 GPUs, along with network and management equipment, deployment services and 36 months of IT operations support. The total contract value is $8.208 million, excluding import duties and taxes. The deal gives Exascale a defined hardware-and-services order and adds a substantial contract to the company’s commercial narrative.
WISeSat.Space Satellite Launches and Post-Quantum Security Put a New Space-Technology Stock on the Map
WISeSat.Space (NASDAQ:SAIQ) entered the public market in October following the completion of its business combination with Columbus Acquisition Corp. Its shares began trading on Nasdaq under SAIQ on October 2. The company is focused on secure satellite communications for Internet of Things applications, combining space infrastructure with cybersecurity and digital identity technology. Its investment narrative sits at the intersection of satellite connectivity, critical infrastructure protection and the emerging need to prepare communications systems for future quantum-computing threats.
A significant technical milestone followed on October 20, when WISeSat announced the successful launch and deployment of FOSSASAT-2E27, a 6U satellite developed by strategic partner FOSSA Systems aboard SpaceX’s Falcon 9 Bandwagon-5 mission. Equipped with secure-element technology from SEALSQ (NASDAQ: LAES), the satellite offers another platform for testing hardware-based cybersecurity in actual space conditions. The companies intend to use a collaboration covering up to six selected satellite missions to progressively validate security technologies, including potential next-generation post-quantum components, subject to technical readiness and integration.
About 24/7 Market News
In today's fast-moving markets, visibility is everything and 24/7 Market News (24/7) provides a powerful suite of investor relations and public relations solutions designed to elevate your company’s profile quickly and effectively. Whether you're an established name seeking broader awareness, or a micro-cap looking to break out of obscurity, 24/7 delivers targeted, high-impact coverage through timely news distribution, analyst report placements, featured editorials, and multi-channel amplification across financial platforms, social media, and investor communities. Our services help cut through the noise, attract institutional interest, drive exposure, and build long-term shareholder credibility, all while maintaining full SEC compliance and transparency. For Analyst Report coverage, custom IR campaigns, press release syndication, or other tailored investor and public relations solutions, contact [email protected] to discuss how 24/7 can help accelerate your company’s visibility and valuation trajectory.
PAID EDITORIAL DISCLOSURE: This is a paid editorial communication intended for informational purposes only. 24/7 is compensated by NTHI to provide ongoing news coverage of expected upcoming catalysts and events as well as market outreach services. For further disclosure information, please click here. This should not be construed as financial or investment advice. Trading involves substantial risk; consult your financial advisor.
Important Editorial Note: 247 highlights companies approaching significant catalysts and inflection points. This report reflects information available at the time of publication. Since developments can occur rapidly, readers should independently verify current information and review all company filings and disclosures.
CONTACT:
24/7 Market News
[email protected]
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company's ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company's ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company's filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.